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Capecitabine is an orally administered chemotherapeutic drug used in the treatment of 
colorectal and breast cancer, as well as of metastatic disease, either as a single agent or 
combined with other agents (1). 
A 63 -year-old man presented with painful penile and scrotal ulcerations (Figure 1). Four 
years prior to admission, the patient underwent ileocecal resection for cecum cancer (pT3, N1, 
M0, Duke`s C) with metastases in the mesocolic lymph nodes. He received 6 cycles of Mayo 
Clinic adjuvant regimen consisting of 5-fluorouracil (5-FU) and leucovorin (folinic acid). 
Three years after resection, positron emission tomography - computed tomography (PET/CT) 
revealed metastases in the mediastinal and para-aortic lymph nodes and lungs. Following the 
surgical treatment, the pathohistological finding was consistent with metastatic 
adenocarcinoma of the colon. Two months after the second surgery the patient was started on 
XELIRI (irinotecan and capecitabine) + bevacizumab. At the end of the first cycle, the patient 
was complaining of tingling and burning sensation on the tips of his fingers and toes. During 
the second cycle, he was complaining of the painful redness of his feet and palms. On 
physical examination, a marked erythema of his palms and feet was noted and hand-foot 
syndrome (palmar-plantar erythrodysesthesia, PPE) was diagnosed (Figures 2a and 2b). A 
skin barrier cream and moisturized ointments together with a short course of potent topical 
corticosteroids were prescribed, but they did not relieve the symptoms. At the beginning of 
the fourth cycle of chemotherapy, erythema was followed by painful ulcerations of his penis 
and scrotum (Figure 1). Capecitabine was thus discontinued. The penile and scrotal 
ulcerations together with the hand and foot symptoms resolved within 3 weeks of 
discontinuing capecitabine. Three months after reintroducing capecitabine, the patient re-
developed genital and scrotal redness and ulcerations, together with hand and foot redness.  
The most common cutaneous side effect of capecitabine is hand-foot syndrome, also known 
as palmar–plantar erythrodysesthesia (PPE). Other cutaneous adverse reactions such as 
alopecia, nail changes, skin discoloration, cutaneous hyperpigmentation, photosensitivity 
reaction, and radiation recall syndrome have also been reported.
2-4
 Recently, a case report 
described a delayed-type hypersensitivity reaction,
5
 while another report described 
scleroderma-like skin changes associated with PPE associated with capecitabine
6
. However, 
to our knowledge, the coexistence of both genital and scrotal ulcerations together with PPE 
has been described in three patients only.
7, 8 
For that reason, there is no consistent grading 
system to describe scrotal and penile involvement associated with capecitabine. Sapp et al
7
 
suggest that the manifestations of PPE are similar to the symptoms experienced with scrotal 
and penile involvement, and that this variant should be incorporated into the grading system 
describing PPE. Grade 1 PPE is characterized by the following symptoms: numbness, 
dysesthesia and tingling in the hands and feet.
9
 In Grade 1, chemotherapy is usually continued 
and a skin barrier cream and moisturized ointment are prescribed.
10
 In Grade 2 PPE, patients 
experience painful erythema with swelling of palms and soles, while Grade 3 is characterized 
by desquamation, ulceration, blistering and severe pain.
9
 In this grade, the dose of 
chemotherapy is either maintained or reduced by 25%.
9
 Managing Grade 3 PPE includes 
interrupting one cycle of chemotherapy, followed by the dose adjustment alongside moist 
ointment and supportive care.
10
 Genital and scrotal ulcerations fall into Grade 3 severity. 
The burning sensation of the skin, together with painful ulcerations, especially in the genital 
region, have negative influence on the quality of life, belief in recovery, and often result with 
the need of permanent or temporary interruption of the oncological treatment, which may 
endanger the completion of the therapy.  
This case represents a rare side-effect of capecitabine. Based on the significant pain and 
discomfort that our patient suffered, it is important for practitioners to recognize this entity as 
a side effect of capecitabine, in order to minimize discomfort and complications. 
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Figure 1 
Ulceration of the penis and scrotum in patient with metastatic colon carcinoma treated with 
capecitabine 
 
Figure 2a and 2b 
Palmar-plantar erythrodysesthesia in patient with metastatic colon carcinoma treated with 
capecitabine 
 
 
